Abstract: A method for determining whether a Systemic lupus erythematosus (SLE) patient is undergoing a pre-flare event, the method comprising obtaining a blood, serum, plasma, or saliva sample from the SLE patient; assessing a level of expression for each of a plurality of biomarkers, the plurality of biomarkers comprising OPN, MCP-1/CCL2, MCP-3/CCL7, IL-17A, TNFRII, TNFRI, IL-4, IL-5, BLyS, TNF?, and IL-7; determining a Lupus Flare Risk Prediction Index (LFPI) for the patient based upon the level of expression for each of a plurality of biomarkers; and based upon the LFPI, determining whether the patient is undergoing a pre-flare event.

Abstract: An artificial intelligence (AI) system and methods for management of an autoimmune or inflammatory condition, disorder or disease in a patient for the diagnosis, prognosis, or risk assessment of symptoms thereof. The AI system includes patient and provider applications and a payer application interface accessible via a communications network. The system contains a data-driven recommendation engine using machine learning and/or deep learning based on active monitoring of patients with an autoimmune or inflammatory-related condition, disorder, or disease. The system can alert clinicians to an impending symptom flare and provide a treatment solution that reduces symptom severity, reduces or eliminates the onset.